| Business Type | Exporter, Supplier, Retailer |
| Strength | 2 Mg |
| Packaging | Box |
| Color | White |
| Click to view more | |
Product Details
COMPOSITION:
Each Tablet contains: 2.254 mg Trametinib dimethyl sulfoxide equivalent to Trametinib……………… 2mg
INDICATION:
LuciTram is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
LuciTram is indicated, in combination with dabrafenib, for:
· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations.
· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.
· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.COMPOSITION:
Each Tablet contains: 2.254 mg Trametinib dimethyl sulfoxide equivalent to Trametinib……………… 2mg
INDICATION:
LuciTram is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
LuciTram is indicated, in combination with dabrafenib, for:
· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations.
· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.
· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.COMPOSITION:
Each Tablet contains: 2.254 mg Trametinib dimethyl sulfoxide equivalent to Trametinib……………… 2mg
INDICATION:
LuciTram is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
LuciTram is indicated, in combination with dabrafenib, for:
· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations.
· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.
· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.
* Currently we are not Accepting Orders for this Product.
